The purpose of this clinical research study is to assess the safety and immunogenicity of the investigational MenPenta vaccine in adults and adolescents.

The MenPenta vaccine is developed as a combination vaccine using meningococcal ACYW-TT conjugate antigens of licensed MenQuadfi® vaccine and the investigational multicomponent meningococcal B antigens (Sanofi MenB vaccine) that is intended to provide protection against the five most epidemiologically relevant neisseria meningitidis serogroups worldwide.

To qualify for the study, you must be:

  • Aged 18 to 25 years or 10 to 17 years on the day of inclusion
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and judgment of the investigator.
  • Other criteria may apply*

*There are multiple studies available to participate in and each may require different criteria to be approved as a participant.

To learn more about this trial and to find out if you qualify, please call 402.934.0044 or complete the form on our Contact page.